The FDA has approved Merck's once-daily cholesterol pill Lipfendra (enlicitide), marking the first oral PCSK9 inhibitor.

People whose LDL cholesterol is in the normal range—even those without metabolic risk factors—may yet have levels of apolipoprotein B (apoB) that predict an elevated risk of future atherosclerotic ...

A deeper look at what one supercentenarian’s labs can teach us about aging, cholesterol, and what really matters for ...

The Martin-Hopkins equation to assess low-density lipoprotein (LDL) cholesterol levels in blood samples has been used by ...

In a traditional observational analysis, associations of LDL-C with incident chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), and all-cause mortality were U-shaped or ...

Four types of food should be worked into your diet in a bid to reduce the amount of cholesterol in your body, according to ...

This article was originally featured on Knowable Magazine. When C. Michael Gibson of Boston saw his doctor in the spring of 2023, the blood test results were confusing. His cholesterol levels were ...

Merck said on Thursday the U.S. FDA has approved its cholesterol pill, Lipfendra, the first of its kind to receive the health ...

A small interfering RNA (siRNA) investigational therapy that inhibits a gene involved in lipoprotein metabolism has been shown in a clinical trial led by Mount Sinai researchers to significantly ...